[Applications of antisense oligonucleotides in oncology].
The development of biotechnologies offers considerable potential for new therapeutical approaches, targetting nucleic acids as information bearing molecules responsible for various pathologies. Gene therapy has, up to now, mainly aimed at compensating deficiencies of gene expression, through complex molecular and cellular constructions. Recently, an increasing interest has focused on short nucleotidic sequences (thus relatively easy to synthetize), or oligonucleotides, which could be able to specifically block the expression of mutated or overexpressed genes. When the target of these oligonucleotides is the mRNA of such genes, the strategy is called "antisense". This strategy has already led to a number of successful results in experimental models in vitro. Much more rare are actual effects in animal models and clinical trials are just being sketched. A review on the current state of the art will enlighten the physiological potential of these new molecules but also underline the still numerous issues before controlling therapeutical applications.
Pierga
J Y
JY
Laboratoire de physiopathologie, institut Curie, Paris, France.
Cammilleri
S
S
Benyahia
B
B
Magdelénat
H
H
D000818:Animals; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009374:Neoplasms, Experimental; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D013873:Thionucleotides / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use
D016376:Oligonucleotides, Antisense; D013873:Thionucleotides
Applications des oligonucléotides antisens en cancérologie.